(RTTNews) - Silo Pharma, Inc. (SILO), Monday announced positive results from a pre-clinical study of SPC-15 showing potential for the treatment of major depressive disorder, and other severe stress-related conditions.
Animal models indicated that SPC-15, a 5-HT4R agonist, with an NMDAR antagonist might offer additional efficacy in treating severe conditions compared to using either agent alone. The combination therapy showed a marked reduction in stress behaviors in animal models.
Silo expects to develop SPC-15 as an intranasal prophylactic treatment for PTSD.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
